Title: When to Wait for More Evidence? Real Options Analysis in Proton Therapy
Authors: Grutters, Janneke P. C ×
Abrams, Keith R
De Ruysscher, Dirk
Pijls-Johannesma, Madelon
Peters, Hans J. M
Beutner, Eric
Lambin, Philippe
Joore, Manuela A #
Issue Date: Dec-2011
Publisher: AlphaMed Press
Series Title: The Oncologist vol:16 issue:12 pages:1752-1761
Abstract: Purpose. Trends suggest that cancer spending growth will accelerate. One method for controlling costs is to examine whether the benefits of new technologies are worth the extra costs. However, especially new and emerging technologies are often more costly, while limited clinical evidence of superiority is available. In that situation it is often unclear whether to adopt the new technology now, with the risk of investing in a suboptimal therapy, or to wait for more evidence, with the risk of withholding patients their optimal treatment. This trade-off is especially difficult when it is costly to reverse the decision to adopt a technology, as is the case for proton therapy. Real options analysis, a technique originating from financial economics, assists in making this trade-off.
ISSN: 1083-7159
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science